Pluri (PLUR) Current Deferred Revenue (2011 - 2024)

Pluri (PLUR) reported Current Deferred Revenue of $101000.0 for Q1 2024, up 1342.86% quarter-over-quarter from $7000.0 in Q2 2023.

Pluri (PLUR) Current Deferred Revenue (2011 - 2024) Analysis & Trends

Pluri (PLUR) has 8 years of Current Deferred Revenue data on file, last reported at $101000.0 in Q1 2024.

Current Deferred Revenue for Q1 2024 came in at $101000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $101000.0 (changed N/A YoY), and the FY2023 annual result was $7000.0, changed N/A from the prior year.
Current Deferred Revenue advanced to $101000.0 in Q1 2024 per PLUR's latest filing, from $7000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $101000.0 in Q1 2024 and troughed at $7000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Pluri	21.39 Mn	21.87 Mn	86,000.00

Download Data